PharmaTelevision - Genentech`s James Sabry discusses their approach to changes in the deal environment

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Genentech`s James Sabry discusses their approach to changes in the deal environment

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to James Sabry, Vice President of Genentech Partnering.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Relationship between Genentech and Roche

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington. On this show I have James Sabry, who is Vice President of Genentech Partnering, welcome.

James Sabry:

Thank you Fintan.

Fintan Walton:

James, we talked last year with Dan Zabrowski, we talked a lot about the relationship between Genentech and Roche I think that is pretty well established now, but just how is that relationship going?

James Sabry:

It continues to go really well Fintan, I know we did talk last year about that and about how we both Genentech and Roche have separate research and early development groups that feed into a common global late stage development commercial and manufacturing group. I think people get that now, they get that we are autonomous centres that partnering can happen with each group there may be advantages of going with Roche for certain assets, going with Genentech for certain assets and we are finding now that partners understand that message is out there both groups are very active and we feel and the survey seem to corraborate this that Genentech and Roche is the ideal partner in fact the number one partner in surveys in the last year, last year or two and so we are very happy with how that's worked out.

Fintan Walton:

Okay, and if anybody who's got relationship with one another continue that relationship and just contact?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

James Sabry

Vice President

James Sabry MD, PhD., has been the Chief Executive Officer and President of Ar"te Therapeutics Inc., since July 2008. Dr. Sabry co-founded Cytokinetics Incorporated., in August 1997 and has been its Consultant since April 1, 2008. James Sabry serves as Vice President of Partnering at Genentech, Inc. He has a wealth of drug discovery, development, and biotechnology management experience. Dr. Sabry served as the Chief Executive Officer of Cytokinetics Incorporated, from August 1997 to January 2006 and also as its President from August 1997 to February 2006. He has been the Chairman of Scientific Advisory Board at Cytokinetics Incorporated, since April 1, 2008. Dr. Sabry served as an Executive Chairman of Cytokinetics Incorporated, from January 22, 2007 to March 31, 2008 and also served as its Chairman from April 1, 2008 to March 16, 2010. He is a Member of Dean's Council of the Kennedy School of Government at Harvard University. He serves as a Director of HopeLab and Arete Therapeutics Inc. He served as an Executive Director of Cytokinetics Incorporated from August 1997 to March 16, 2010. He serves as a Member of Advisory Boards of California Institute of Quantitative Biosciences. He held faculty positions at the University of California, San Francisco and Harvard Medical School from 1984 to 1987. Dr. Sabry received a M.D. from Queen's University and a PhD in Cell Biology from the University of California, San Francisco.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Genentech

Genentech was founded more than 35 years ago, in 1976, by the late venture capitalist Robert A. Swanson and the biochemist Dr. Herbert W. Boyer. In the early 1970s, Boyer and geneticist Stanley Cohen pioneered a new scientific field called recombinant DNA technology. Upon learning about this development, Swanson placed a call to Boyer and requested a meeting. Boyer agreed to give the young entrepreneur 10 minutes of his time. Swanson's enthusiasm for the technology and his faith in its commercial potential were contagious, and the meeting extended from 10 minutes to three hours; by its conclusion, Genentech was born. Though Swanson and Boyer faced skepticism from both the academic and business communities, they forged ahead with their idea. The company's goal was to develop a new generation of therapeutics created from genetically engineered copies of naturally occurring molecules important in human health and disease. Within a few short years, Genentech scientists proved it was possible to make medicines by splicing genes into fast-growing bacteria that produced therapeuticproteins. Today Genentech continues to use genetic engineering techniques and advanced technologies to develop medicines that address significant unmet needs and provide clinical benefits to millions of patients worldwide. In March 2009, Genentech became a member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.